Published in Jpn J Cancer Res on January 01, 2002
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem (2009) 1.12
Novel strategies for reversing platinum resistance. Drug Resist Updat (2009) 1.00
Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet (2012) 0.78
ATP7B expression confers multidrug resistance through drug sequestration. Oncotarget (2016) 0.75
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget (2016) 0.75
Expression of ATP7B in human gastric cardiac carcinomas in comparison with distal gastric carcinomas. World J Gastroenterol (2006) 0.75
Roles of Copper-Binding Proteins in Breast Cancer. Int J Mol Sci (2017) 0.75
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer (2010) 2.52
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol (2012) 2.27
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Thymidine phosphorylase gene mutation is not a primary cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern Med (2006) 2.09
Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.03
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets (2012) 2.00
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med (2006) 1.98
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol (2005) 1.64
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res (2007) 1.54
Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. J Immunol Methods (2004) 1.53
RAP55, a cytoplasmic mRNP component, represses translation in Xenopus oocytes. J Biol Chem (2006) 1.52
Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem Biol (2003) 1.47
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev (2009) 1.45
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res (2007) 1.45
Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biol Ther (2010) 1.45
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Int J Clin Oncol (2005) 1.42
Neutrophil gelatinase-associated lipocalin acts as a protective factor against H(2)O(2) toxicity. Arch Med Res (2008) 1.40
Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem (2012) 1.39
Distribution of artificial radionuclides in abandoned cattle in the evacuation zone of the Fukushima Daiichi nuclear power plant. PLoS One (2013) 1.39
Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol (2011) 1.38
Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res (2002) 1.37
Integrin targeted therapeutics. Theranostics (2011) 1.36
Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets (2007) 1.35
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer (2002) 1.34
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem (2005) 1.34
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat (2010) 1.33
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer (2009) 1.30
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol (2011) 1.30
Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett (2002) 1.29
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology (2009) 1.29
Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest (2008) 1.28
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med (2010) 1.28
Fast scanning tomosynthesis for the detection of pulmonary nodules: diagnostic performance compared with chest radiography, using multidetector-row computed tomography as the reference. Invest Radiol (2011) 1.26
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol (2005) 1.26
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem (2002) 1.26
Spontaneous fractures and quality of life in cerebral palsy. Lancet (2004) 1.26
Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem (2006) 1.25
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem (2002) 1.25
Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol (2005) 1.24
Expression of twist and wnt in human breast cancer. Anticancer Res (2005) 1.23
Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis. Bone (2005) 1.23
Forkhead transcription factor Foxf2 (LUN)-deficient mice exhibit abnormal development of secondary palate. Dev Biol (2003) 1.23
Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci (2011) 1.22
Salivary gland progenitor cells induced by duct ligation differentiate into hepatic and pancreatic lineages. Hepatology (2003) 1.22
The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone (2009) 1.20
Effects of radioactive caesium on bull testes after the Fukushima nuclear plant accident. Sci Rep (2013) 1.20
A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep (2009) 1.20
Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer (2003) 1.19
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One (2012) 1.19
A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res (2007) 1.18
Comparison of a variable-number tandem-repeat (VNTR) method for typing Mycobacterium avium with mycobacterial interspersed repetitive-unit-VNTR and IS1245 restriction fragment length polymorphism typing. J Clin Microbiol (2009) 1.18
Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium. Genes Chromosomes Cancer (2009) 1.18
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A (2012) 1.18
Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation. J Nucl Med (2012) 1.17
Primary osteosarcoma of the breast. Breast Cancer (2004) 1.17
A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J Immunol (2006) 1.17
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc Natl Acad Sci U S A (2006) 1.16
Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem (2006) 1.16
Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 1.16
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci (2007) 1.14
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer (2010) 1.14
Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. Lancet Oncol (2002) 1.14
Cirp protects against tumor necrosis factor-alpha-induced apoptosis via activation of extracellular signal-regulated kinase. Biochim Biophys Acta (2006) 1.13
Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep (2011) 1.13
Design and synthesis of bis-amide and hydrazide-containing derivatives of malonic acid as potential HIV-1 integrase inhibitors. Molecules (2008) 1.13
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther (2004) 1.12
Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes. Antiviral Res (2009) 1.12
Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors. Bioorg Med Chem (2008) 1.12
Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β. J Biol Chem (2013) 1.11
Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorg Med Chem Lett (2007) 1.11
Efficient synthesis and utilization of phenyl-substituted heteroaromatic carboxylic acids as aryl diketo acid isosteres in the design of novel HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2008) 1.10
Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem (2012) 1.10
Mining the NCI antiviral compounds for HIV-1 integrase inhibitors. Bioorg Med Chem (2006) 1.10
Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J Med Chem (2004) 1.10
Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer (2002) 1.09
Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J Med Chem (2006) 1.09
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res (2005) 1.09
Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol (2013) 1.09
Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci (2008) 1.08
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol (2011) 1.07
Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int J Cancer (2009) 1.07